Senti Biosciences Holdings, Inc. (SNTI)
Nasdaq · Healthcare · Biotechnology
$0.3451+7.07%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $10.8M
- 52-week range
- $0.29 – $2.88
- 52-week change
- −81.39%
- EPS (trailing)
- −$1.72
Fiscal year to Dec 2025
- Revenue
- $22K
- Net income
- −$61.4M
- Operating margin
- −312631.8%
- Diluted EPS
- −$2.73
- Free cash flow
- −$43.6M
From the company’s annual report on SEC EDGAR.
About Senti Biosciences Holdings, Inc.
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc.
Headquarters: South San Francisco, United States · 39 employees · sentibio.com